Cereno Scientific

"BIO-Europe Fall is a cornerstone for advancing collaborations in the life science community, bringing together innovators, pharma, and investors from around the globe. With FDA Fast Track designation recently granted for our lead program CS1 in pulmonary arterial hypertension (PAH) and positive Phase I data from our second HDAC inhibitor, CS014, targeting idiopathic pulmonary fibrosis (IPF), we have strong momentum across our pipeline. We look forward to engage in meaningful discussions that can support the advancement of our mission to deliver pioneering treatments for patients with rare cardiovascular and pulmonary diseases," said Sten R. Sörensen, CEO of Cereno Scientific.

Rahul Agrawal, CMO and Head of R&D, will also participate in a panel discussion hosted by IQVIA Institute titled "Accessing the U.S. Market: What's Ahead for European Biotechs?", on November 4, 15:30 - 16:15 CET on the Exhibition Hall Stage.

To schedule a meeting with Sten R. Sörensen, CEO, and Rahul Agrawal, CMO and Head of R&D register at BIO-Europe Registration> or send an email to business.development@cerenoscientific.com.

BIO-Europe is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Innovation Organization (BIO). The 2025 edition is expected to host around 5,000 attendees from approximately 3,000 companies across 60 countries, making it the largest life science partnering event in Europe.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email:  tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and pulmonary hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.